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MinireviewBringing Order to the Glutamate
Chaos in Schizophrenia
tamatergic neurons are, therefore, the exclusive means
by which aberrant information is transferred within and




genetic linkage studies have strongly implicated excit-Pittsburgh, Pennsylvania 15260
atory neurotransmission in schizophrenia. The gluta-
mate system is, therefore, emerging as a promising and
mechanistically relevant novel therapeutic target.Recent genetic linkage studies complement the exist-
Evidence for Excitatory Neurotransmissioning evidence that implicates abnormalities in NMDA
Involvement in Schizophreniareceptor-mediated neurotransmission in the patho-
Abnormal CSF levels of glutamate and postmortem glu-physiology of schizophrenia. At the same time, ad-
tamate receptor binding in schizophrenic individualsvances in our understanding of the complex mecha-
have been reported since the 1970s. However, the limita-nisms that modulate the function of NMDA receptors
tions of these crude measures prevented them fromsuggest several novel sites for pharmacological ma-
being taken seriously. The glutamate theory of schizo-nipulation of these receptors. This presents exciting
phrenia was brought into the mainstream as a result ofopportunities for rational rather than serendipitous
more sophisticated analysis of postmortem brains ofdiscovery of therapeutics for schizophrenia.
schizophrenics (e.g., Deakin et al., 1989; Clinton et al.,
2002; for a recent review, see Konradi and Heckers,Background
2003) and the discovery that the potent psychotomi-The introduction of several new antipsychotic drugs in
metic drug phencyclidine (PCP) is an antagonist of thethe last decade promised to treat schizophrenia more
NMDA subtype of glutamate receptor (Javitt and Zukin,efficaciously than conventional antipsychotics, and with-
1991). Phencyclidine, introduced in the 1950s as a dis-out the unwanted side effects. These drugs, which were
sociative anesthetic, caused postoperative hallucina-modeled after clozapine, reduce dopamine receptor
tions and psychosis. In patients with schizophrenia, PCPfunction. However, a discouraging outcome of treatment
led to profound exacerbation of preexisting symptoms.with these drugs is emerging: they do not substantially
Recent clinical trials in healthy volunteers using the PCPimprove clinical outcome for schizophrenia and, worse,
analog ketamine have further established that NMDAsome produce dangerous side effects, such as weight
antagonist treatment produces transient psychosis, dis-gain, diabetes, and elevations in blood lipids. There is
rupted affect, and cognitive deficits that are similar tonow an increasing awareness that to move the status of
those observed in schizophrenia (Krystal et al., 1994;schizophrenia treatment forward, truly novel therapeutic
Newcomer et al., 1999; Lahti et al., 2001). Animal studiesoptions must be considered (Hyman and Fenton, 2003).
using selective pharmacological ligands or transgenicSchizophrenia is characterized by failures in nearly all
manipulation of NMDA receptor subunits also indicate aaspects of higher-order behavior (Hirsch and Wein-
role for NMDA receptors in a wide spectrum of behaviorsberger, 2003), including (1) disruption of information pro-
that are relevant to schizophrenia (Moghaddam and Ad-cessing and sensory perception, leading to thought dis-
ams, 1998; Mohn et al., 1999). The impressive aspectorder, hallucinations, and paranoia; (2) abnormal mood
of both basic and clinical findings with NMDA antago-and affect, influencing a host of behaviors ranging from
nists is that administration of a single dose of the antago-social interaction to personal hygiene; (3) profound cog-
nist is sufficient to produce these behavioral effects.nitive impairments that encompass most aspects of
Other treatments that produce schizophrenia-like symp-
cognition, including attention, short-term memory, and
toms in humans and animals generally involve chronic
behavioral flexibility; and (4) movement abnormalities,
treatments, lesions, or mutations. This suggests that tran-
including stereotypy, catatonia, echopraxia, abnormal sient changes in the functional state of the NMDA recep-
posture and limb movements, which are generally ig- tor may be sufficient for expression of schizophrenia-
nored because they are not included in current diagnosis like symptoms.
criteria. Although different schools of thought have em- A transient disruption in NMDA receptor function is,
phasized varying sets of symptoms as the “core” of the in fact, an ideal mechanism to underlie the profound
disease and have implicated different brain regions as behavioral abnormalities observed in schizophrenia.
the primary site of pathology, our current understanding NMDA receptors are ion channels that are coincidence
of behavioral and systems neuroscience dictates that detectors because they are gated simultaneously by
such a multifaceted failure of normal behavior must in- voltage and two ligands, glutamate and glycine. Rela-
volve most, if not all, frontal cortical systems, the limbic tively subtle disruptions in mechanisms that influence
system, the basal ganglia, and the thalamus. Reciprocal either membrane potential or ligand binding to various
connections between corticocortical, corticolimbic, and regulatory sites on the receptor may have a profound
corticothalamic projections are exclusively glutamatergic. effect on the probability and duration of NMDA channel
In addition, efferents from all cortical areas, as well as opening and, therefore, on behaviors that are modulated
key corticolimbic regions such as the hippocampus and by NMDA receptors. Examples of factors that directly
amygdala, to motor effector sites are glutamatergic. Glu- influence the function of the NMDA receptor are de-
picted in Figure 1. These include several regulatory sites
on the NMDA receptor itself; presynaptic mechanisms*Correspondence: moghaddam@bns.pitt.edu
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Figure 1. Schematic Illustration of Some of
the Components of the Excitatory Synapse
and Potential Sites for Pharmacological Inter-
vention in Schizophrenia
Recently described schizophrenia suscepti-
bility genes that can influence the activity of
this synapse are depicted in dotted gray cir-
cles (see text for details). Some of the targets
for pharmacological intervention include the
glycine and D-serine binding site on the NR1
subunits of the NMDA receptor, the Glycine
transporter (Gly T), and potentiators of meta-
botropic glutamate (mGlu) receptors, in par-
ticular mGlu5, which positively modulates
NMDA receptors through activation of the G
protein Gq, and mGlu2/3, which regulate the
release of glutamate.
that regulate the release of glutamate, glycine, and regulate G protein signaling. In particular, RGS4 inhibits
signaling by the mGlu5 receptor (Saugstad et al., 1998).D-serine (an endogenous ligand for the glycine binding
site); transporter systems on neurons and glia that regu- This subtype of metabotropic glutamate receptor is lo-
calized near the NMDA receptors, and its stimulationlate synaptic levels of these ligands; and the level of
activity of excitatory and inhibitory ion channel receptors potentiates NMDA-mediated currents. The mGlu5-NMDA
interaction requires activation of Gq, a G protein thatsuch as AMPA and GABAA that directly influence the
membrane potential. In addition, other receptors, such is regulated by RGS4. A fourth example of a recently
identified candidate gene is dysbindin (Straub et al.,as ErbB4 and mGlu5, influence the kinetics of NMDA
receptors through interactions with intracellular signal 2002). Dysbindin, through the dystropin protein com-
plex, recruits molecules such as nitric oxide synthasetransduction mechanisms and the postsynaptic density
(PSD). Thus, even in the absence of any abnormalities (NOS) that influence NMDA receptor activity by in-
teracting with PSD. Finally, the PPP3CC gene, whichin the number or structure of NMDA receptors, dysregu-
lation of any of these regulatory sites may have a pro- encodes the calcineurin  subunit, has recently been
associated with schizophrenia (Gerber et al., 2003). Cal-found influence on behavior by disrupting NMDA recep-
tor function in an activity-dependent manner. cineurin is critical for certain types of NMDA-mediated
plasticity. There are also a number of other related link-Assuming that aberrant NMDA receptor signaling is
involved in the pathophysiology of schizophrenia, genes age findings, including the GRIN1 gene (Martucci et al.,
2003), which encodes the NR1 subunit of the NMDAthat encode or regulate any of the large number of pro-
teins that influence the function of NMDA receptors receptor, and GRM3 (Fujii et al., 2003), the mGlu3 recep-
tor gene, that await replication in larger and more diversewould be plausible susceptibility genes for this disease.
Recent genetic linkage studies identifying candidate sample sizes.
Clearly, the genes outlined above serve functions thatsusceptibility genes for schizophrenia support this no-
tion (Harrison and Owen, 2003). For example, neuregulin may be unrelated to NMDA receptors. More importantly,
these linkage studies are at different stages of replica-1 (NRG1), which has recently been associated with
schizophrenia (Stefansson et al., 2002), regulates expres- tion and have differing degrees of statistical validation.
However, it is significant that influencing excitatory neu-sion of glutamate receptor subunits and directly activates
ErbB4 receptors. This member of the ErbB family of rotransmission appears to be the common link among
most recently described susceptibility genes for schizo-tyrosine kinases is colocalized with the NMDA receptor
and is thought to regulate the kinetic properties of the phrenia. This suggests that a complex set of genetic
factors produce a similar behavioral syndrome acrossNMDA receptor by phosphorylating the NR2 subunit of
the NMDA receptor. Accordingly, mutant mice heterozy- diverse patient populations through a common functional
pathway: the modulation of NMDA receptor function.gous for NRG1 (or ErbB4) display a behavioral profile
similar to animals treated with NMDA antagonists and Implications for Etiology and Pathophysiology
of Schizophreniahave fewer functional NMDA receptors. Another recently
described susceptibility gene is G72, a newly discovered The recent genetic findings begin to rebut the long-
standing skepticism that has surrounded the idea ofhuman gene on chromosome 13q34 (Chumakov et al.,
2002). G72 interacts with the gene for the enzyme NMDA receptor dysfunction in schizophrenia. This legiti-
mate skepticism arises from the fact that NMDA recep-D-amino acid oxidase (DAAO), which oxidizes D-serine
and thereby reduces its synaptic availability. A third tors are ubiquitous and are implicated in a wide range
of physiological processes critical to brain function,gene that has recently been implicated in schizophrenia
is RGS4 (Chowdari et al., 2002). RGS proteins negatively such as development, plasticity, and excitotoxicity. Ab-
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normalities in NMDA-mediated neurotransmission might, These trials have consistently shown improvement in
cognitive functioning and the so-called negative symp-therefore, be expected to profoundly affect most as-
pects of brain function beginning at the earliest stages toms of schizophrenia when agonists of the glycine site,
such as D-serine, D-cycloserine, or n-methyl-glycine,of development rather than causing selective behavioral
abnormalities manifested primarily after adolescence, were administered to patients with chronic schizophre-
nia stabilized on neuroleptics.as in schizophrenia. However, the genetic and postmor-
tem findings do not support gross abnormalities at the The positive results of these clinical trials are facilitat-
ing the development of more specific ligands that havelevel of NMDA receptor subunit structure, receptor num-
ber, or cellular localization. Rather, the vulnerability to shown promise in preclinical models. Among these are
the following. (1) Specific blockers of the glycine trans-develop schizophrenia now appears to arise from
changes in the function of genes that encode proteins porter (Javitt, 2002), which would be expected to in-
crease the synaptic levels of glycine and enhancewhich modulate some of the downstream effects of
NMDA receptor activation. This suggests that selective NMDA-mediated functions. (2) Positive modulators of
mGlu5 receptors, a group of metabotropic glutamateand activity-dependent changes in the efficiency of
NMDA receptor-mediated signaling, as opposed to co- receptors that synergistically enhance NMDA receptor-
mediated currents. Recent behavioral data with systemi-lossal disruptions in NMDA receptor function, may be
a culprit in schizophrenia. cally active ligands of mGlu5 receptors suggest that the
molecular and cellular interaction between NMDA andConsidering the well-established involvement of
NMDA receptors in neuronal development, the recent mGlu5 receptors extends to regulation of complex be-
havior (Kinney et al., 2003). Because of the rapid ratefindings are also consistent with notions that schizo-
phrenia is a developmental disorder and that epigenetic of mGlu5 receptor desensitization, mGlu5 receptor
agonists are not considered to be effective therapeuticfactors play a major role in the disease process. A dis-
ruption in epigenetic regulation of development at criti- targets; however, allosteric sites on the receptor that
positively modulate its function have recently been dis-cal periods may alter the expression of the vulnerable
genes and affect the development of cortical and limbic covered (Knoflach et al., 2001). Potentiators of these
sites are now considered to be important candidatesneurons by modifying NMDA-mediated signal transduc-
tion. A large epidemiological literature, in fact, associ- for positive modulation of NMDA receptor function and
treatment of schizophrenia. (3) Agonists of mGlu2/3 re-ates environmental factors such as maternal health and
birth complications to an increased propensity to devel- ceptors, another group of metabotropic glutamate re-
ceptors that autoregulate the release of glutamate andop schizophrenia (Hirsch and Weinberger, 2003). Envi-
ronmental factors, including stress, which is a profound were found to normalize the behavioral effects of NMDA
antagonists (Moghaddam and Adams, 1998). Recentactivator of cortical glutamate pathways (Moghaddam,
2002), are also involved in the onset or exacerbation of clinical trials in healthy volunteers show that treatment
with an mGluR2/3 agonist reduces schizophrenia-likesymptoms of schizophrenia, suggesting that epigenetic
factors may continue to influence the expression of the cognitive deficits induced by ketamine (Krystal et al.,
2003), suggesting that potentiation of mGlu2/3 receptoraffected genes in adulthood. Questions, however, re-
main as to why a disruption in the function of NMDA function may be an effective treatment strategy for the
cognitive symptoms of schizophrenia. Clinical trials inreceptors throughout the brain, albeit subtle, would lead
to very selective behavioral abnormalities that are asso- schizophrenia, at least as an adjunct therapy, may not
be far in the future.ciated with schizophrenia. Despite the ubiquitous nature
of NMDA receptors, it is important to keep in mind that Conclusions
Given the accumulating literature implicating gluta-administration of low doses of NMDA antagonists pro-
duces a behavioral profile in healthy volunteers that is matergic dysfunction in schizophrenia, there is great
optimism that basic and clinical researchers will takesimilar to schizophrenia (Krystal et al., 1994). Thus, as
our knowledge of the role of NMDA receptors in regulat- advantage of the available animal models and the large
number of modulatory targets on NMDA and relateding complex behavior evolves, it may become apparent
that reductions in NMDA-mediated signal transduction receptors to design and test treatment strategies that
could fine tune abnormal glutamate neurotransmissionhave a selective influence on cognitive and affective
functions that are related to symptoms of schizophrenia. in schizophrenia. This approach represents a concep-
tual shift in a field that remains firm in the belief that aImplication for Treatment
The recent genetic findings are also enticing the field hyperdopaminergic state is the primary culprit in schizo-
phrenia. Dopamine D2 receptor antagonists are, in fact,to put more emphasis on developing ligands for modula-
tory sites that influence the glutamate synapse. The the only known effective treatment for psychosis. How-
ever, postmortem and genetic studies have generallyschizophrenia-like effects of NMDA antagonists in healthy
volunteers suggest that the primary glutamatergic abnor- failed to show abnormalities with the D2 receptor. In
addition, the simple idea that an overactive dopaminemality in schizophrenia is reduced NMDA function. Ther-
apeutic strategies, therefore, have focused mostly on system elicits psychosis is not supported by the fact
that dopamine D1 antagonists, which are far more effec-enhancing NMDA receptor function through mecha-
nisms that positively modulate this receptor (Javitt, tive than D2 antagonists in blocking hyperdopaminergic
behavioral states in laboratory animals, do not alleviate2002). Results of recent clinical trials testing this hypoth-
esis have been promising. At least seven placebo-con- but may even exacerbate psychosis. This worsening of
symptoms, on the other hand, is consistent with antrolled studies have focused on the strategy of enhanc-
ing NMDA receptor function by targeting the glycine NMDA-deficient state in schizophrenia, because a con-
sequence of reduced NMDA receptor activity may bemodulatory site (Coyle et al., 2002; Tsai et al., 2003).
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